The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.

about

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.New facets of antifungal therapy.

P2860

Q28067726-B91AF5F1-36F5-4125-BEB6-FC13F81903B6 Q36406975-0DDEC79D-5220-45A8-BF8D-2DD4E7ADA30B Q38797864-E5C28D00-9DCD-439B-9232-A1A62CD363D6

P2860

The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.

Item

http://www.wikidata.org/entity/Q38534865

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The 'cephalosporin era' of tri ...... of invasive fungal infections.

@en

type

Item

label

The 'cephalosporin era' of tri ...... of invasive fungal infections.

@en

prefLabel

The 'cephalosporin era' of tri ...... of invasive fungal infections.

@en

P1476

The 'cephalosporin era' of tri ...... of invasive fungal infections.

@en

P2093

Dimitrios P Kontoyiannis

http://www.w3.org/2001/XMLSchema#string

P2860

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

In vitro antifungal activity of isavuconazole against Madurella mycetomatis

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.

Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

P304

1543-1558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.1057500

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Maria Nina Chitasombat

P577

2015-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26100603

http://www.w3.org/2001/XMLSchema#string

The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.

about

P2860

P2860

The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698